zr89-rituximab
mAbexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02251964)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 89-zirconium
Oral
No
Parenteral
No
Topical
No
Also known as
- zr89-rituximab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02251964 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2014 | Free University of Amsterdam, St. Antonius Hospital, Nieuwegein |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Free University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2014 |
| St. Antonius Hospital, Nieuwegein | Academic/Hospital | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1